© Reuters. FILE PHOTO: The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020. REUTERS/Arnd Wiegmann/File photo) on Tuesday raised its full-year earnings forecast for the third time on strong drug sales, after its generic drugs business
The Swiss drugmaker said in a statement that it expects group core operating income to grow by a percentage of"mid to high teens" in 2023, up from"low double-digit to mid teens" predicted previously.We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other.
{username} Just Now Share Follow this postUnfollow this post Save Saved. See Saved Items . This comment has already been saved in your Saved Items Author's response{commentContent} Reply 00 Report {username} Just NowAuthor's response Share Follow this postUnfollow this post Save Saved. See Saved Items .